NSE: MANKIND · 26 October 2026
- Mankind Pharma Limited shares advanced 4.49% on Monday, closing at ₹2,312.00 after trading within a daily range of ₹2,215.00 and ₹2,333.90.
- The company announced a strategic acquisition of a majority stake in Armed Cell Therapeutics, marking its entry into next-generation CAR-T therapies. Management noted that the transaction aims to strengthen the company's R&D capabilities for future growth in specialized oncology treatments.
- Trading volume was 1.65 times the 20-day average daily volume.
Why is Mankind Pharma share price rising on 26 October 2026?
Mankind Pharma Limited shares advanced 4.49% on Monday, closing at ₹2,312.00 after trading within a daily range of ₹2,215.00 and ₹2,333.90.
The broader market and healthcare sector provided supportive tailwinds during the trading session. The benchmark Nifty rose by 0.68%, while the Nifty Pharma sector index outperformed with a gain of 1.76%. Mankind Pharma's upward price action contributed to the broader sectoral momentum, building on a modest 5-day return of 1.60% despite a 20-day trailing loss of 7.52%.
The positive price movement coincided with the release of the company's financial results for the second quarter and half year ended September 30, 2026. Mankind Pharma reported strong operational performance, with consolidated revenue from operations growing 17.3% year-on-year to ₹4,338 crore and profit after tax surging 37.7% to ₹716 crore. Management highlighted robust domestic business growth and continued outperformance in chronic and acute therapeutic segments as key drivers of the period's results.
10.25 lakh shares traded by 26 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 6.21 lakh shares (1.65 times). The five-day average daily volume was 7.39 lakh shares. Separately, the NSE report for 26 October 2026 showed 4.56 lakh shares delivered, representing 44.46% of that day’s traded volume. The same report recorded 56,520 trades.
The stock's 4.49% gain was supported by heavy trading volumes and favourable sectoral performance, directly coinciding with the announcement of strong Q2 FY27 financial results that showed robust revenue and profit growth.
Latest Company Developments
The company announced a strategic acquisition of a majority stake in Armed Cell Therapeutics, marking its entry into next-generation CAR-T therapies. Management noted that the transaction aims to strengthen the company's R&D capabilities for future growth in specialized oncology treatments.
This strategic transaction expands Mankind Pharma's technological capabilities and product pipeline into advanced cellular therapies.
Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
a press release dated October 15, 2026, titled "Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies ".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 11.31% on 30 September 2026. This compares with 10.87% on 30 June 2026, a change of +0.44 percentage points.
The filing reported 36 MF/UTI holders.
What to Watch Next
- Management commentary and guidance provided during the upcoming earnings conference call
- Post-earnings delivery volume sustainability relative to the 20-day average
- Integration progress and R&D updates regarding the recently announced Armed Cell Therapeutics acquisition
- Continued market share trends across key chronic and acute therapeutic brands
Other Dated Coverage
- Mankind Pharma Share Price Today: Why MANKIND Is Falling 2.77% | 23 October 2026 — 23 October 2026
- Mankind Pharma in Focus After Acquiring Majority Stake in Armed Cell Therapeutics | 16 October 2026 — 16 October 2026
- Mankind Pharma Share Price Today: Why MANKIND Is Falling 2.47% | 14 October 2026 — 14 October 2026
More Mankind Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Mankind Pharma company news?
The company announced a strategic acquisition of a majority stake in Armed Cell Therapeutics, marking its entry into next-generation CAR-T therapies. Management noted that the transaction aims to strengthen the company's R&D capabilities for future growth in specialized oncology treatments.
How strong was Mankind Pharma’s trading volume?
10.25 lakh shares traded, 1.65 times the 20-day average daily volume. The price and volume data are dated 26 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.